Assuntos
Galinhas , Fezes/microbiologia , Doenças das Aves Domésticas/tratamento farmacológico , Salmonelose Animal , Salmonella typhimurium/efeitos dos fármacos , Virginiamicina/uso terapêutico , Animais , Infecções por Salmonella/tratamento farmacológico , Salmonella typhimurium/isolamento & purificaçãoAssuntos
Salmonelose Animal/microbiologia , Doenças dos Suínos/microbiologia , Virginiamicina/administração & dosagem , Administração Oral , Ração Animal , Animais , Resistência Microbiana a Medicamentos , Escherichia coli/efeitos dos fármacos , Fezes/microbiologia , Abrigo para Animais , Salmonella typhimurium/efeitos dos fármacos , Salmonella typhimurium/isolamento & purificação , Suínos , Virginiamicina/farmacologia , Virginiamicina/uso terapêuticoRESUMO
Acute toxicity of oxibendazole was assessed with single oral doses given to mice (4 to 32 g/kg of body weight), sheep (230 to 600 mg/kg), and cattle (600 mg/kg); there were no ill effects. Subacute toxicity did not occur with multiple doses given 5 days to cattle (30 to 75 mg/kg/day) and to sheep (10 to 50 mg/kg/day). Chronic effects did not occur with daily doses of 3 to 30 mg/kg given 98 days to rats and dogs. Teratogenicity of the compound was studied in mice, rats, and sheep medicated at a dose level of 30 mg of oxibendazole/kg and in cattle given 75 mg/kg on selected dates during pregnancy. Microscopically, rodent fetuses seemed normal, and on gross physical examination, lambs and calves were free of malformations and ossification variations.
Assuntos
Benzimidazóis/toxicidade , Carbamatos/toxicidade , Doenças dos Bovinos/induzido quimicamente , Doenças dos Ovinos/induzido quimicamente , Teratogênicos , Anormalidades Induzidas por Medicamentos/veterinária , Animais , Aspartato Aminotransferases/sangue , Bovinos , Colinesterases/sangue , Cães , Feminino , Masculino , Camundongos , Osteogênese , Gravidez , Ratos , OvinosRESUMO
The anthelmintic agent methyl 5(6)-butyl-2-benzimidazolecarbamate (Parbendazole) was transformed to two of its animal metabolites, methyl 5(6)-(4-hydroxybutyl)-2-benzimidazolecarbamate and methyl 5(6)-3-(carboxypropyl)-2-benzimidazolecarbamate, by the filamentous fungus Cunninghamella bainieri ATCC 9244. The transformation pathway was shown to be through the 4-hydroxybutyl product to the 3-carboxypropyl product. The reaction favored accumulation of the latter product.